LifeSciences BC > News > Member Announcements

Print Friendly

Innovative Targeting Solutions Collaboration with Janssen Biotech Achieves Multiple Milestones

May 24, 2017

SAN FRANCISCO, CA and VANCOUVER, May 24, 2017 /CNW/ – Innovative Targeting Solutions Inc. (ITS) today announced the successful achievement of three milestones from its collaboration with Janssen Biotech, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The collaboration utilizes Innovative Targeting Solutions’ proprietary HuTARG™ research platform to discover antibody candidates … Continue reading Innovative Targeting Solutions Collaboration with Janssen Biotech Achieves Multiple Milestones

Arbutus Presents HBV Drug Combination Studies at ICAR

May 23, 2017

Combinations of Arbutus’ RNAi or Capsid Assets with Approved Drugs Demonstrate Complementary ActivityDr. Michael J. Sofia, Arbutus’ Chief Scientific Officer, Awarded International Society of Antiviral Research Gertrude Elion Award VANCOUVER, British Columbia and WARMINSTER, Pa., May 22, 2017 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today … Continue reading Arbutus Presents HBV Drug Combination Studies at ICAR

DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2017 Financial Results

May 18, 2017
DelMar Pharmaceuticals, Inc.

Company will host a business update conference call and webcast on Wednesday May 24, 2017 at 4:30 PM EST – VANCOUVER, British Columbia and MENLO PARK, Calif., May 18, 2017 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” and the “Company”), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today … Continue reading DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2017 Financial Results

Novelogics Biotechnology, Inc. & CDRD partner to advance novel cancer treatment

May 17, 2017
The Centre for Drug Research and Development (CDRD)

May 17, 2017 – Vancouver, BC: Novelogics Biotechnology, Inc. announced today that it has entered into a research agreement with The Centre for Drug Research and Development (CDRD), Canada’s national drug development and commercialization centre, to further characterize Novelogics’ internally-developed antibody immunotherapy for treating cancer. The proprietary technology behind Novelogics’ innovation involves discovery and development … Continue reading Novelogics Biotechnology, Inc. & CDRD partner to advance novel cancer treatment

Aequus Validates Need for Improved Delivery Methods of Medical Cannabis

May 16, 2017
Aequus Pharmaceuticals Inc.

VANCOUVER, BC. May 15, 2017 – Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today announced results from a medical cannabis needs assessment survey it deployed involving 410 physicians in Canada and the United States. Aequus sought to … Continue reading Aequus Validates Need for Improved Delivery Methods of Medical Cannabis

DelMar Formalizes Collaboration with PRA Health Sciences for Phase 3 Trial of VAL-083 in Recurrent Glioblastoma Multiforme (GBM)

May 11, 2017
DelMar Pharmaceuticals, Inc.

VANCOUVER, British Columbia and MENLO PARK, Calif., May 11, 2017 /PRNewswire/ — DelMar Pharmaceuticals (Nasdaq: DMPI) (“DelMar” and the “Company”), a biopharmaceutical company focused on developing new cancer therapies, today announced the formalization of an agreement with PRA Health Sciences (Nasdaq: PRAH), a leading contract research organization (CRO) to conduct the Company’s Phase 3 trial of … Continue reading DelMar Formalizes Collaboration with PRA Health Sciences for Phase 3 Trial of VAL-083 in Recurrent Glioblastoma Multiforme (GBM)

Xenon Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update

May 10, 2017
About Xenon Pharmaceuticals Inc.

BURNABY, British Columbia, May 09, 2017 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company today, reported its financial results for the quarter ended March 31, 2017, and provided a corporate update for 2017. Dr. Simon Pimstone, Xenon’s President and Chief Executive Officer, said, “We continue to leverage our expertise in human genetics and … Continue reading Xenon Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update

Aquinox Pharmaceuticals Announces First Quarter 2017 Financial Results

May 9, 2017
Aquinox Pharmaceuticals, Inc.

Aquinox Pharmaceuticals Announces First Quarter 2017 Financial Results VANCOUVER, British Columbia, May 09, 2017 (GLOBE NEWSWIRE) — Aquinox Pharmaceuticals, Inc. (“Aquinox“) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, today provided a corporate update and reported financial results for the first quarter ending March 31, 2017. … Continue reading Aquinox Pharmaceuticals Announces First Quarter 2017 Financial Results

DelMar to Present Poster of Clinical Research with VAL-083 in Patients with Chemo-Resistant Glioblastoma (“GBM”) at ASCO Annual Meeting

May 8, 2017
DelMar Pharmaceuticals, Inc.

VANCOUVER, British Columbia and MENLO PARK, Calif., April 27, 2017 /PRNewswire/ — DelMar Pharmaceuticals (Nasdaq: DMPI) (“DelMar” and the “Company”), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that it will present a poster at the Annual Meeting of the American Society of Clinical Oncology (ASCO) held in … Continue reading DelMar to Present Poster of Clinical Research with VAL-083 in Patients with Chemo-Resistant Glioblastoma (“GBM”) at ASCO Annual Meeting

Qu Biologics invited to present Research Data at International Scientific Meetings

May 8, 2017
Qu Biologics Inc.

VANCOUVER, British Columbia, May 03, 2017 (GLOBE NEWSWIRE) — Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to restore the body’s innate immune system, is pleased to announce that Qu Biologics’ scientists will be presenting their research findings at several upcoming international scientific meetings. The presented … Continue reading Qu Biologics invited to present Research Data at International Scientific Meetings